FATE vs FRT · rev $3.4M vs rev $1.28B
Fate Therapeutics Inc (FATE) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.
FRT (FRT) common stock.
Latest reported FATE revenue for 2026-06-30 was $3.4M. Net income was -$61.4M. FATE currently screens at market cap $331.0M.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
FATE currently screens at market cap $331.0M. FRT currently screens at market cap $0.
Not investment advice. Open the FATE and FRT stock pages for the full models.
Not investment advice.